SERPINA1 11478G→A variant, serum α1-antitrypsin, exacerbation frequency and FEV1 decline in COPD
- PMID: 21335450
- DOI: 10.1136/thx.2010.152975
SERPINA1 11478G→A variant, serum α1-antitrypsin, exacerbation frequency and FEV1 decline in COPD
Abstract
Background: The α(1)-antitrypsin 11478G→A polymorphism may be associated with attenuated acute α(1)-antitrypsin responses. It was hypothesised that patients with chronic obstructive pulmonary disease (COPD) and this mutation have accelerated lung function decline.
Objective: To assess whether the 11478G→A polymorphism is associated with attenuated α(1)-antitrypsin responses at COPD exacerbation, and therefore accelerated lung function decline.
Methods: Lung function decline by genotype was examined in the English Longitudinal Study of Ageing (ELSA; n=1805) and Whitehall II (n=2733) studies. 204 patients with COPD were genotyped in the London cohort and serum α(1)-antitrypsin concentration was measured at baseline and (n=92) exacerbation.
Results: The 11478G→A genotype frequencies did not vary between COPD cases and controls, or between COPD frequent and infrequent exacerbators. Subjects with the rare A allele experienced more rapid lung function decline in the Whitehall II (A vs non-A: 16 vs 4 ml/year p=0.02) but not ELSA (29 vs 34 ml/year, p=0.46) or London cohorts (26 vs 38 ml/year, p=0.06). Decline was not greater in frequent exacerbator A versus non-A carriers (20 vs 24 ml/year, p=0.58). Upregulation of α(1)-antitrypsin at exacerbation was not demonstrated, even in patients homozygous for the common allele (median exacerbation change -0.07 g/l 11478GG, p=0.87 and -0.09 g/l 11478AA/GA, p=0.92; p=0.90 for difference). In patients with the A allele, there was no correlation between serum α(1)-antitrypsin and serum interleukin 6 (IL-6) concentrations.
Conclusion: The 11478G→A α(1)-antitrypsin polymorphism is not associated with increased risk of developing COPD, nor accelerated lung function decline. Serum α(1)-antitrypsin may not be upregulated early at COPD exacerbation. In patients with the 11478G→A polymorphism there was no relationship between the serum α(1)-antitrypsin and serum IL-6 concentrations.
Similar articles
-
Haplotype in SERPINA1 (AAT) Is Associated with Reduced Risk for COPD in a Mexican Mestizo Population.Int J Mol Sci. 2019 Dec 27;21(1):195. doi: 10.3390/ijms21010195. Int J Mol Sci. 2019. PMID: 31892136 Free PMC article.
-
The Effects of Rare SERPINA1 Variants on Lung Function and Emphysema in SPIROMICS.Am J Respir Crit Care Med. 2020 Mar 1;201(5):540-554. doi: 10.1164/rccm.201904-0769OC. Am J Respir Crit Care Med. 2020. PMID: 31661293 Free PMC article.
-
Serum Alpha-1 Antitrypsin Levels and the Clinical Course of Chronic Obstructive Pulmonary Disease.Int J Chron Obstruct Pulmon Dis. 2019 Dec 10;14:2885-2893. doi: 10.2147/COPD.S225365. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2019. PMID: 31849461 Free PMC article.
-
Genetic predisposition to accelerated decline of lung function in COPD.Int J Chron Obstruct Pulmon Dis. 2007;2(2):117-9. Int J Chron Obstruct Pulmon Dis. 2007. PMID: 18044683 Free PMC article. Review.
-
Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.Int J Chron Obstruct Pulmon Dis. 2017 May 2;12:1295-1308. doi: 10.2147/COPD.S130440. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28496314 Free PMC article. Review.
Cited by
-
Haplotype in SERPINA1 (AAT) Is Associated with Reduced Risk for COPD in a Mexican Mestizo Population.Int J Mol Sci. 2019 Dec 27;21(1):195. doi: 10.3390/ijms21010195. Int J Mol Sci. 2019. PMID: 31892136 Free PMC article.
-
Genetic profile and patient-reported outcomes in chronic obstructive pulmonary disease: A systematic review.PLoS One. 2018 Jun 21;13(6):e0198920. doi: 10.1371/journal.pone.0198920. eCollection 2018. PLoS One. 2018. PMID: 29927965 Free PMC article.
-
Updates on the COPD gene list.Int J Chron Obstruct Pulmon Dis. 2012;7:607-31. doi: 10.2147/COPD.S35294. Epub 2012 Sep 18. Int J Chron Obstruct Pulmon Dis. 2012. PMID: 23055711 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- PG/03/029/BHF_/British Heart Foundation/United Kingdom
- AG13196/AG/NIA NIH HHS/United States
- RG/02/005/BHF_/British Heart Foundation/United Kingdom
- G0902037/MRC_/Medical Research Council/United Kingdom
- HL36310/HL/NHLBI NIH HHS/United States
- R01AG1764406S1/AG/NIA NIH HHS/United States
- HS06516/HS/AHRQ HHS/United States
- R01AG24233/AG/NIA NIH HHS/United States
- RG/07/008/23674/BHF_/British Heart Foundation/United Kingdom
- G19/35/MRC_/Medical Research Council/United Kingdom
- G8802774/MRC_/Medical Research Council/United Kingdom
- RG/05/014/BHF_/British Heart Foundation/United Kingdom
- G0100222/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous